Lotronex
NDC 54766-894
Product Information
Lotronex is a NDA-approved product labeled by Sebela Pharmaceuticals Inc.. Alosetron is used to treat women with severe irritable bowel syndrome (IBS) who have diarrhea as the main problem. It is supplied as a white product. This product entry covers the primary NDC 54766-894 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
GX;EX1
Code Structure Chart
Product Details
What is NDC 54766-894?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- ALOSETRON HYDROCHLORIDE (UNII: 2F5R1A46YW)
- ALOSETRON (UNII: 13Z9HTH115) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- LACTOSE (UNII: J2B2A4N98G)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- STARCH, CORN (UNII: O8232NY3SJ)
- HYPROMELLOSES (UNII: 3NXW29V3WO)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- TRIACETIN (UNII: XHX3C3X673)
* Please review the full disclaimer at the bottom of this page.
Patient Education
Alosetron
Alosetron is used to treat diarrhea, pain, cramps, and the feeling of an urgent need to have bowel movements caused by irritable bowel syndrome (IBS; a condition that causes stomach pain, bloating, constipation, and diarrhea) in women who have diarrhea as their main symptom and have not been helped by other treatments. Alosetron is in a class of medications called 5-HT3 receptor antagonists. Alosetron works by slowing the movement of stool (bowel movements) through the intestines.
[Learn More]
* Please review the full disclaimer at the bottom of this page.